The O-antigen negative ∆wbaV mutant of Salmonella enterica serovar Enteritidis shows adaptive resistance to antimicrobial peptides and elicits colitis in streptomycin pretreated mouse model

Gut Pathogens
Sangeeta JaiswalMrutyunjay Suar

Abstract

Salmonella enterica serovar Enteritidis, the most common cause of human gastroenteritis, employs several virulence factors including lipopolysaccharide (LPS) for infection and establishment of disease inside the host. The LPS of S. enterica serovar Enteritidis consists of lipid A, core oligosaccharide and O-antigen (OAg). The OAg consists of repeating units containing different sugars. The sugars of OAg are synthesized and assembled by a set of enzymes encoded by genes organized into clusters. Present study focuses on the effect of deletion of genes involved in biosynthesis of OAg repeating units on resistance to antimicrobial peptides and virulence in mice. In the present study, the OAg biosynthesis was impaired by deleting tyv, prt and wbaV genes involved in tyvelose biosynthesis and its transfer to OAg. The virulence phenotype of resulting mutants was evaluated by assessing resistance to antimicrobial peptides, serum complement, adhesion, invasion and in vivo colonization. Deletion of the above three genes resulted in the production of OAg-negative LPS. All the OAg-negative mutants showed phenotype reported for rough strains. Interestingly, ΔwbaV mutant showed increased resistance against antimicrobial peptides and normal hu...Continue Reading

References

Mar 1, 1991·Infection and Immunity·L V CollinsJ Hackett
Jan 1, 1989·The Journal of Infectious Diseases·B D ForrestD Rowley
Dec 1, 1996·Trends in Microbiology·P R ReevesP D Rick
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Mar 29, 2001·The Journal of Biological Chemistry·C DartigalongueS Raina
Aug 25, 2001·Journal of Endotoxin Research·J S Gunn
Jun 5, 2002·Annual Review of Biochemistry·Christian R H Raetz, Chris Whitfield
Jan 1, 1965·Proceedings of the National Academy of Sciences of the United States of America·L D ZELEZNICKB L HORECKER
Nov 4, 2004·Molecular Microbiology·Eirwen MorganTimothy S Wallis
Feb 22, 2005·Molecular Microbiology·Christina Tam, Dominique Missiakas
Oct 31, 2006·Methods in Molecular Biology·Cristina L MaroldaMiguel A Valvano
Dec 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yuhua LiRoy Curtiss
Feb 18, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shannon E MajowiczUNKNOWN International Collaboration on Enteric Disease 'Burden of Illness' Studies
May 16, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yanyan LiRobert K Ernst

❮ Previous
Next ❯

Methods Mentioned

BETA
GTase
electrophoresis
phosphotransferase
PCR

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.